When does Eliquis (apixaban) lose exclusivity in the US?
Eliquis will have a generic in the US only after key patent/exclusivity protections tied to apixaban end and regulators can approve an abbreviated generic (or another form such as a biosimilar is not relevant here because apixaban is a small-molecule drug, not a biologic). Patent and exclusivity timing has been the main driver of when generic competition can launch.
When could a generic launch happen based on patent status?
The most practical way to estimate the US “generic date” is to track the apixaban patent expiration and any later exclusivity barriers (for example, additional patents covering specific formulations, dosing, or methods of use can delay entry even after the first patent expires). DrugPatentWatch.com tracks these US patent events and is one of the clearest public resources for checking the current expected timeline. [1]
Has a generic already launched?
If a generic had already launched, pharmacies would typically show multiple “apixaban” products beyond Eliquis branded tablets. To verify whether a true generic is currently available (and which versions are FDA-approved), you can cross-check the latest updates on DrugPatentWatch.com and also check the FDA’s “Approved Drug Products” listings for apixaban. [1]
What’s the difference between “generic availability” and “patent expiry”?
Even after patents expire, a generic company may still need time for FDA approval and product launch. Also, “patent expiry” can be different from “exclusivity expiry” if there are secondary patents or other legal barriers still in force at the time the FDA would otherwise approve the generic. This is why patent-event trackers are commonly used to answer “when will Eliquis go generic?” rather than relying on a single date. [1]
If you share whether you mean generic apixaban tablets for atrial fibrillation/stroke prevention, DVT/PE treatment, or the 2.5 mg vs 5 mg strengths, I can help narrow the question to the specific protection and timing those products are tied to (the answer can vary by strength and patent family).
Sources:
[1] https://www.drugpatentwatch.com/